SG Americas Securities LLC Reduces Stock Position in Elanco Animal Health Incorporated $ELAN
SG Americas Securities LLC significantly reduced its stake in Elanco Animal Health (NYSE: ELAN) by 65.1% in the first quarter, selling 62,227 shares. Despite this reduction, Elanco reported stronger-than-expected quarterly results, with EPS of $0.40 and revenue of $1.37 billion, surpassing analyst estimates. Analyst sentiment remains "Moderate Buy" with an average price target of $28.55, and several firms have recently raised their targets.
Form 4 Elanco Animal Health For: 2 July By Investing.com
This article is a brief announcement from Investing.com about the filing of Form 4 for Elanco Animal Health on July 2nd. It provides no further details beyond stating the company and the date of the filing. The article appears to be an automated notification of a regulatory filing.
ETFs Investing in Elanco Animal Health, Inc. Stocks
The article lists numerous ETFs that hold Elanco Animal Health, Inc. stock, providing details such as market value, weight in the fund, issuer, management style, expense ratio, assets under management (AUM), and 3-year NAV total return. This information is intended to help investors find accessible opportunities with lower risk through diversified funds.
Form 4 Elanco Animal Health For: 2 July By Investing.com
This article announces a Form 4 filing for Elanco Animal Health on July 2nd. It is a brief news alert from Investing.com and includes financial market data such as indices, commodities, and bond yields, as well as popular news headlines and trending stocks. The primary content is the announcement of the financial filing.
Elanco (ELAN) executive awarded 25,620 stock options at $24.09 strike price
David S. Kinard, an executive at Elanco Animal Health Inc. (ELAN), was granted 25,620 employee stock options with an exercise price of $24.09 per share. These options will vest in three equal annual installments beginning March 1, 2027, and will expire on July 1, 2036. Following this grant, Kinard directly holds 25,620 stock options, representing the right to purchase company shares.
Elanco (ELAN) director converts cash fees into 584 deferred stock units
Elanco Animal Health director K. Anand converted her cash director retainer fees into 584.1121 Deferred Stock Units (DSUs) on June 30, 2026, at an implied price of $24.61 per unit. These DSUs are economically equivalent to common stock shares and will be settled in stock upon her separation from the Board, bringing her total holdings to 10,079.5639 DSUs. This transaction, reported via a Form 4 filing, is a compensation-related award rather than an open-market trade.
Elanco (NYSE: ELAN) CFO gets new deferred stock unit award
Elanco Animal Health's EVP and CFO, Robert M. VanHimbergen, received a grant of 8.0187 deferred stock units, increasing his total holdings to 108.8506 units. These units, valued at $24.57 each, represent a right to receive company common stock or its cash equivalent upon termination of employment or in a specified future year, as per the Executive Deferral and Stock Match Plan. This transaction was reported in a Form 4 filing, indicating a neutral impact and sentiment.
Is the Options Market Predicting a Spike in Elanco Animal Health Stock?
The article explores whether the options market is signaling a significant move for Elanco Animal Health (ELAN) stock, noting the high implied volatility in a specific call option. It explains that high implied volatility often precedes large stock movements due to anticipated events or investor expectations. Despite this options activity, analysts currently rate Elanco Animal Health as a Zacks Rank #3 (Hold), with recent downward revisions to earnings estimates.
Elanco (ELAN) CEO Jeffrey Simmons receives 115 deferred stock units grant
Elanco Animal Health Inc. CEO Jeffrey N. Simmons was granted 115.0562 deferred stock units, each valued at $24.57. This compensation-related award increases his total holdings to 24,657.0048 deferred stock units. These units will settle in cash or company shares upon the termination of his employment or in a specified future year, as per the Executive Deferral and Stock Match Plan.
Elanco (NYSE: ELAN) executive receives new deferred stock unit award
Elanco executive Rajeev A. Modi has been granted 60.1111 deferred stock units (DSUs) at a reference price of $24.57 per unit, bringing his total DSU holdings to 9,523.1312. These DSUs represent the right to receive Elanco common stock or cash equivalent, and will settle after employment termination or in a specified future year under the Executive Deferral and Stock Match Plan. This transaction was reported in a Form 4 filing and is considered neutral in impact and sentiment.
Elanco Commits To Supporting US In Fight Against Screwworm
Elanco Animal Health has reaffirmed its commitment to combating the New World screwworm threat in the US, following the first confirmed case in Texas. The company states it will provide resources and treatment options for veterinarians, livestock producers, and pet owners. Elanco, with significant experience in animal health, is offering a portfolio of products, some under FDA Conditional Approval or Emergency Use Authorization, to treat and prevent screwworm infestations.
Enterprise value to EBIT forward of Elanco Animal Health Incorporated – NYSE:ELAN
This article provides financial information for Elanco Animal Health Incorporated (NYSE:ELAN), specifically focusing on its enterprise value to EBIT forward ratio. The content appears to be a stub or a section of a larger financial data display from TradingView, indicating a placeholder for specific financial metrics and historical data.
Piper Sandler reiterates Elanco stock rating on defensive positioning By Investing.com
Piper Sandler has reiterated an Overweight rating and a $30.00 price target for Elanco Animal Health due to its defensive positioning in the animal health sector. Despite structural headwinds from declining puppy visits, Elanco is expected to perform better than its peers because of its diversified exposure to farm animal products, over-the-counter products, and international pet health. The company has also recently expanded its product portfolio, including new vaccines and treatments, and launched Elanco Ventures to foster innovation.
Piper Sandler Maintains Elanco Animal Health(ELAN.US) With Buy Rating, Maintains Target Price $30
Piper Sandler has reiterated its Buy rating on Elanco Animal Health (ELAN.US), maintaining a price target of $30. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Price to sales forward of Elanco Animal Health, Inc. – MUN:5EA
The article displays the "Price to sales forward" metric for Elanco Animal Health, Inc. (MUN:5EA) on the Munich Stock Exchange. It provides a placeholder for the period, value, and change of this financial indicator.
Price to earnings forward of Elanco Animal Health Incorporated – NYSE:ELAN
This page provides financial information for Elanco Animal Health Incorporated (NYSE: ELAN) regarding its Price to Earnings (forward) ratio. It shows the value for a specified period and the change in both absolute and percentage terms. The content indicates the data is derived from TradingView, with market data from ICE Data Services and reference data from FactSet.
Louisiana State Employees Retirement System Buys New Shares in Elanco Animal Health Incorporated $ELAN
Louisiana State Employees Retirement System has initiated a new position in Elanco Animal Health (NYSE:ELAN), acquiring 144,100 shares valued at approximately $3.45 million during the first quarter. Elanco Animal Health reported strong first-quarter earnings, beating analyst expectations with $0.40 EPS and revenue up 14.9% year-over-year. Analysts maintain a "Moderate Buy" consensus rating with an average target price of $28.55, and several institutional investors have adjusted their holdings in the company.
Elanco working to manage parasitic fly’s arrival in U.S.
Elanco Animal Health is developing solutions to combat the New World screwworm, a parasitic fly that lays eggs in open wounds and can be fatal to livestock and pets. The fly's re-emergence in South and Central America, including Mexico, poses a significant threat to the U.S. livestock industry. Elanco is collaborating with government agencies and other organizations to implement strategies, including a sterile insect technique, to prevent the fly's establishment in the United States and protect animal health.
OP Asset Management Ltd Makes New Investment in Elanco Animal Health Incorporated $ELAN
OP Asset Management Ltd has made a new investment in Elanco Animal Health (ELAN), acquiring 341,444 shares valued at approximately $8.17 million. This investment positions Elanco with a "Moderate Buy" consensus rating among analysts and an average target price of $28.55. The company recently surpassed Q1 expectations with $0.40 EPS and $1.37 billion in revenue, further supported by recent insider share purchases.
Elanco Animal Health Inc (ELAN) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Elanco Animal Health Inc (ELAN), focusing on its support and resistance levels, various technical indicators, and moving averages. ELAN's current price momentum score is 7.40, placing it well within its industry, and the stock is trading between a resistance level of $26.15 and a support level of $22.68. The analysis suggests a "Buy" signal based on moving averages and a mixed signal from other technical indicators.
Is Elanco Animal Health Incorporated (ELAN) Positioned for Long-Term Growth With Seven Potential Blockbuster Launches?
Elanco Animal Health Incorporated (ELAN) is targeting long-term growth driven by seven potential blockbuster product launches and the establishment of Elanco Ventures, a corporate venture capital initiative. TD Cowen maintained a Buy rating on ELAN, raising its price target to $32, citing these launches and a diversified portfolio as key drivers for projected revenue growth over 5% and EPS growth of around 10% through 2032. Elanco Ventures will invest $25 million in early-stage animal health innovations, focusing on therapeutic solutions and enabling technologies.
Argus Research Maintains Elanco Animal Health(ELAN.US) With Buy Rating
Argus Research has reiterated its Buy rating for Elanco Animal Health (ELAN.US). This indicates a continued positive outlook from the research firm regarding the company's stock performance.
A Look at Elanco Animal Health Inc (ELAN) After 3.0% Decline -- GF Value $15.57 vs Price $23.18
Elanco Animal Health Inc (ELAN) experienced a 3.0% share price decline, making its current price $23.18, significantly above its GF Value™ of $15.57, indicating it is 48.9% overvalued. Despite this overvaluation and an average GF Score™ of 66/100, insiders have bought $0.2 million worth of shares, signaling confidence. Investors are advised to be cautious due to the potential for a price correction.
Elanco Animal Health Inc (ELAN) Valuation: PE, PB & Fair Value Analysis
The article provides a valuation analysis for Elanco Animal Health Inc (ELAN), noting its current valuation score of 9.14, ranking 46th in the Pharmaceuticals industry. It highlights the company's current P/E ratio of -48.96, which is significantly below its recent high and above its recent low. The report indicates that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Elanco To Launch $25 Million Corporate Venture Capital Platform
Elanco Animal Health is establishing Elanco Ventures, a corporate venture capital platform backed by a $25 million multi-year commitment, set to launch in late 2026. This platform will focus on early-stage investments in therapeutic advancements and supportive technologies within the animal health sector, including the broader One Health landscape. It aims to leverage partnerships within the One Health Innovation District in Indianapolis to foster innovation.
Neurizon, Elanco Ink Long-Term Supply Agreement for Human Health Monepantel
Neurizon Therapeutics and Elanco Animal Health have signed a long-term strategic supply agreement for human health monepantel, the active pharmaceutical ingredient (API) in Neurizon's lead asset, NUZ-001. NUZ-001 is a potential therapy for ALS and other neurodegenerative diseases, currently in a Phase II/III trial. This agreement, an expansion of a previous global license, ensures scalable GMP supply and aims to support Neurizon's commercial readiness and strengthen its CMC infrastructure.
T. Rowe Price Investment Management Inc. Increases Position in Elanco Animal Health Incorporated $ELAN
T. Rowe Price Investment Management Inc. significantly increased its stake in Elanco Animal Health Incorporated ($ELAN) by 11.8% in Q4, adding 3.7 million shares. Elanco reported strong quarterly results, exceeding analyst expectations for EPS and revenue, with a 14.9% year-over-year revenue increase. Insider buying by CEO Jeffrey N. Simmons and Rajeev A. Modi further signals confidence, while analysts maintain a "Moderate Buy" rating with an average target price of $28.55.
Elanco Animal Health Incorporated (NYSE:ELAN) Given Average Recommendation of "Moderate Buy" by Brokerages
Elanco Animal Health (NYSE:ELAN) has received an average "Moderate Buy" rating from 14 brokerages, with a consensus 12-month price target of $28.55. The company recently surpassed quarterly earnings and revenue expectations, reporting EPS of $0.40 on $1.37 billion, and subsequently raised its guidance for Q2 2026 and FY 2026. Insider confidence is high, with CEO Jeffrey N. Simmons and insider Rajeev A. Modi making significant share purchases in May.
ELAN - Elanco Animal Health Inc Stock Price and Quote
This article provides comprehensive financial data, news, and analyst ratings for Elanco Animal Health Inc (ELAN). It covers the company's stock performance, key financial metrics, recent corporate announcements including the launch of Elanco Ventures, new product approvals, and insider trading activities.
Elanco Ventures Expands Animal Health Innovation Ecosystem
Elanco Animal Health has launched Elanco Ventures, an initiative focused on strengthening animal care through emerging technologies and industry collaboration. This program aims to support research and development in areas such as companion animal healthcare, livestock management, biotechnology, and digital health. By fostering innovation, Elanco Ventures seeks to accelerate the development of solutions that improve animal care and agricultural outcomes.
Elanco to launch $25M VC program focused on animal health innovation
Elanco Animal Health is launching a new $25 million venture capital program, Elanco Ventures, to invest in start-ups and early-stage companies focused on animal health innovation. The initiative aims to support advancements in areas like pet health, livestock sustainability, and digital technology. This move highlights Elanco's strategy to partner with emerging companies to drive growth and meet the evolving needs of the animal health market.
Elanco Animal Health Launches Venture Capital Platform
Elanco Animal Health has established Elanco Ventures, a new corporate venture capital platform backed by a $25 million commitment to invest in early-stage animal health companies. This initiative, set to launch in late 2026 and overseen by Eric Steager, aims to foster innovation in therapeutic advancements and supportive technologies within the animal health sector. The company also reported strong financial performance, with non-GAAP EPS and revenue exceeding expectations.
Elanco plans VC platform to fast track animal health innovation
Elanco Animal Health is launching Elanco Ventures, a corporate venture capital platform backed by a $25 million multiyear commitment. This initiative will focus on strategic investments in therapeutic advancements and supportive technologies within the animal health sector, including potential opportunities in the broader One Health landscape. Launching in late 2026 and overseen by Eric Steager, Elanco Ventures aims to accelerate innovation by partnering with early-stage companies, leveraging the One Health Innovation District in Indianapolis.
Elanco to Launch Elanco Ventures with $25 Million Multi-Year Commitment to Accelerate Innovation in Animal Health
Elanco Animal Health is launching Elanco Ventures, a new corporate venture capital platform, with a $25 million multi-year commitment to invest in animal health innovation. The platform will focus on early-stage companies and therapeutic advancements, with an eye on the broader One Health landscape. This initiative aims to leverage external innovation and partnerships, particularly within the One Health Innovation District in Indianapolis, to accelerate progress in the animal health sector.
Elanco bets $25 million on startup tech for animal health
Elanco Animal Health (NYSE: ELAN) announced the launch of Elanco Ventures, a new corporate venture capital platform backed by a $25 million multi-year commitment. This initiative aims to invest in early-stage animal health startups focusing on therapeutic advancements, supportive technologies, and One Health opportunities. The platform, launching in late 2026 and led by Eric Steager, will leverage collaborations within Indianapolis’ One Health Innovation District to accelerate innovation.
ExodusPoint Capital Management LP Buys 491,617 Shares of Elanco Animal Health Incorporated $ELAN
ExodusPoint Capital Management LP significantly increased its stake in Elanco Animal Health Incorporated by 180.9%, purchasing an additional 491,617 shares. This brings their total holdings to 763,331 shares, valued at approximately $17.3 million. The increase follows Elanco's stronger-than-expected quarterly results and raised guidance, alongside constructive analyst sentiment and insider buying.
Elanco (ELAN) CFO VanHimbergen receives deferred stock unit grant under deferral plan
Elanco Animal Health's EVP and CFO, Robert M. VanHimbergen, received a grant of 8.1514 deferred stock units at a reference price of $24.17 per unit. This grant brings his total holdings to 100.8319 deferred stock units. These units are a form of compensation that will settle in cash or shares of Elanco common stock after employment ends or in a specified future year, under the company’s Executive Deferral and Stock Match Plan.
Elanco (ELAN) CEO Jeffrey Simmons receives deferred stock unit grant
Elanco Animal Health (ELAN) CEO Jeffrey N. Simmons received a grant of 116.9603 deferred stock units, valued at $24.17 per unit, as part of a routine compensation-related transaction. This grant increases his total deferred stock unit holdings to 24,541.9486 units. These units will settle in cash or Elanco common shares upon the termination of his employment or in a specified future year, according to the company's Executive Deferral and Stock Match Plan.
Deferred stock award to Elanco (NYSE: ELAN) executive disclosed
Elanco Animal Health Inc. executive, Rajeev A. Modi, received a grant of 61.1059 deferred stock units valued at $24.17 per unit, increasing his total holdings to 9,463.0201 deferred stock units. These units will settle in cash or company common shares upon termination of employment or a specified future year, as part of the Executive Deferral and Stock Match Plan. This transaction, reported via Form 4, is a compensation-related grant and not an open-market purchase or sale.
Elanco Announces USDA Approval of TruCan Ultra Lyme-L4, the First and Only 1/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs
Elanco Animal Health Incorporated (NYSE: ELAN) has received USDA approval for TruCan Ultra Lyme-L4, the first and only 1/2 mL combination vaccine for dogs that protects against both Lyme disease and leptospirosis. This combines two injections into one, making wellness visits more comfortable for pets, and utilizes Elanco's PureFil™ Technology to reduce vaccination reactions. The product aims to address "protection gaps" for these increasingly prevalent canine diseases, with shipping expected to begin in the next 30 days.
Elanco (ELAN) Introduces TruCan Ultra Lyme-L4 Vaccine for Dogs
Elanco Animal Health Inc. (ELAN) has received USDA approval for its TruCan Ultra Lyme-L4 vaccine, a significant advancement in canine disease prevention. This 1/2 mL combination vaccine targets Lyme disease and leptospirosis, offering convenience for pets and owners. With a market cap of $12.07 billion and a GF Score of 66, Elanco shows moderate potential for long-term returns, despite profitability challenges, and has seen recent insider buying activity.
Elanco receives USDA approval for canine combination vaccine By Investing.com
Elanco Animal Health Incorporated received USDA approval for TruCan Ultra Lyme-L4, a canine combination vaccine protecting against Lyme disease and leptospirosis in a single injection. This vaccine expands Elanco's TruCan Ultra Portfolio, addressing a protection gap as over 40% of at-risk dogs in endemic areas lack current Lyme vaccination. The company's stock has surged 75% over the past year, reflecting investor confidence in its innovation pipeline.
Elanco Announces USDA Approval of TruCan™ Ultra Lyme-L4, the First and Only 1/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs
Elanco Animal Health has received USDA approval for TruCan™ Ultra Lyme-L4, the first and only 1/2 mL combination vaccine for dogs that protects against both Lyme disease and leptospirosis. This innovation reduces the number of injections required, enhancing pet comfort during wellness visits, and uses proprietary PureFil™ Technology to minimize vaccination reactions. The product is expected to ship within the next 30 days, addressing critical protection gaps for these two prevalent canine diseases.
New low-volume dog vaccine targets Lyme and leptospirosis in a single shot
Elanco (NYSE: ELAN) has received USDA approval for TruCan™ Ultra Lyme-L4, a pioneering 1/2 mL combination vaccine for dogs that protects against both Lyme disease and leptospirosis. This new vaccine is designed to reduce injection volume and uses proprietary PureFil™ Technology to minimize vaccination reactions. The product is expected to begin shipping within 30 days, addressing a significant protection gap in at-risk canine populations.
Elanco Animal Health Q1 earnings call highlights
The provided content is empty and does not contain any information about Elanco Animal Health's Q1 earnings call. Therefore, no summary can be generated.
Brandes Investment Partners LP Has $95.09 Million Position in Elanco Animal Health Incorporated $ELAN
Brandes Investment Partners LP reduced its stake in Elanco Animal Health (NYSE:ELAN) by 29.3% in the fourth quarter but still holds 4.2 million shares valued at $95.09 million. Elanco reported strong quarterly results, beating EPS and revenue expectations, and analysts maintain a "Moderate Buy" rating with a consensus price target of $28.20. Insider buying also occurred in May, indicating confidence in the company.
Elanco Animal Health Inc (ELAN) Shares Surge 3.5% -- What GF Sco
Elanco Animal Health Inc (ELAN) shares rose 3.5% to $24.50 on June 9, 2026, but are considered 57.7% overvalued according to GuruFocus's GF Value™ estimate of $15.54. Despite a strong momentum score (10/10) within its GF Score™ of 67/100, the company shows concerns in financial strength (5/10) and valuation (3/10). Insider activity reveals $0.2 million in purchases over the last three months with no selling, suggesting insider confidence despite the overvaluation.
Norges Bank Makes New $32.42 Million Investment in Elanco Animal Health Incorporated $ELAN
Norges Bank has initiated a new position in Elanco Animal Health (NYSE:ELAN), acquiring 1.43 million shares valued at about $32.42 million. This investment highlights increasing institutional interest in Elanco, which recently reported strong quarterly results and holds a "Moderate Buy" consensus rating from analysts.
Clearbridge Investments LLC Has $128.37 Million Stock Position in Elanco Animal Health Incorporated $ELAN
Clearbridge Investments LLC slightly reduced its stake in Elanco Animal Health by 3.8% in Q4, but still holds 5.67 million shares valued at $128.4 million. Institutional ownership of ELAN stands at 97.48%. The company recently reported Q1 EPS of $0.40 and revenue of $1.37 billion, exceeding expectations, and analysts maintain a "Moderate Buy" rating with a target price of $28.20.
TD Asset Management Inc Purchases 516,628 Shares of Elanco Animal Health Incorporated $ELAN
TD Asset Management Inc. significantly increased its stake in Elanco Animal Health (NYSE:ELAN) by 47.6% in the fourth quarter, purchasing an additional 516,628 shares and bringing its total holdings to over 1.6 million shares valued at approximately $36.3 million. This increase comes as Elanco reported better-than-expected first-quarter earnings, with EPS of $0.40 against an estimated $0.34 and revenue exceeding forecasts at $1.37 billion. Insiders, including CEO Jeffrey N. Simmons and Rajeev A. Modi, have also recently bought shares, reinforcing a "Moderate Buy" consensus among Wall Street analysts with an average target price of $28.20.
